









Mercado
/
Acciones
/
nasdaq-biib
/

Biogen Inc

BIIB

176.330USD

+1.510+0.86%

Cierre 12/24, 13:00（ET）Cotizaciones retrasadas 15 min

25.87BCap. mercado

16.04P/E TTM



Biogen Inc

176.330

+1.510+0.86%

Descripción general Compañía Finanzas Análisis

Descripción general

Compañía

Finanzas

Análisis

Más Datos de Biogen Inc Compañía

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Información de Biogen Inc



Símbolo de cotizaciónBIIB

Nombre de la empresaBiogen Inc

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoViehbacher (Christopher A)

Número de empleados7605

Tipo de seguridadOrdinary Share

Fin del año fiscalSep 17

Dirección225 Binney Street

CiudadCAMBRIDGE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02142

Teléfono17814642000

Sitio Webhttps://www.biogen.com/

Símbolo de cotizaciónBIIB

Fecha de salida a bolsaSep 17, 1991

Director ejecutivoViehbacher (Christopher A)

Ejecutivos de Biogen Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Mr. Jesus B. Mantas

Independent Director

8.42K

+39.19%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-8.22%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+76.33%

Ms. Susan Langer

Independent Director

3.79K

+166.90%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+55.38%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+12.13%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+28.86%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+1.19%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+23.75%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-16.53%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

Otro

498.00M

18.82%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

1.38B

52.21%

Rest of World

937.60M

35.44%

United states-Revenues from anti-CD20 therapeutic

467.30M

17.66%

Rest of World-Other revenues

244.60M

9.25%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

MS product revenues-TYSABRI

839.80M

31.74%

Spinal Muscular Atrophy-SPINRAZA

543.00M

20.53%

MS product revenues-Fumarate

405.90M

15.34%

MS product revenues-Interferon

246.70M

9.33%

Biosimilar product revenues-BENEPALI

112.10M

4.24%

Otro

498.00M

18.82%

Estadísticas de accionistas

Actualizado: dom., 16 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

11.73%

PRIMECAP Management Company

10.19%

BlackRock Institutional Trust Company, N.A.

5.60%

State Street Investment Management (US)

4.99%

Wellington Management Company, LLP

2.89%

Otro

64.59%

Accionistas

Proporción

The Vanguard Group, Inc.

11.73%

PRIMECAP Management Company

10.19%

BlackRock Institutional Trust Company, N.A.

5.60%

State Street Investment Management (US)

4.99%

Wellington Management Company, LLP

2.89%

Otro

64.59%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

52.68%

Investment Advisor/Hedge Fund

26.60%

Hedge Fund

8.04%

Pension Fund

2.94%

Research Firm

2.45%

Sovereign Wealth Fund

1.59%

Bank and Trust

1.59%

Individual Investor

0.17%

Family Office

0.15%

Otro

3.79%

Participación institucional



Actualizado: lun., 8 de dic

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q4

1994

139.65M

97.81%

+140.37K

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

2023Q3

2150

131.42M

95.94%

-1.80M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

17.21M

11.74%

+255.44K

+1.51%

Jun 30, 2025

PRIMECAP Management Company

15.80M

10.78%

-141.14K

-0.89%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.19M

5.59%

-504.36K

-5.80%

Jun 30, 2025

State Street Investment Management (US)

7.47M

5.09%

+71.90K

+0.97%

Jun 30, 2025

Wellington Management Company, LLP

4.80M

3.27%

+125.98K

+2.70%

Jun 30, 2025

Geode Capital Management, L.L.C.

3.92M

2.67%

+71.29K

+1.85%

Jun 30, 2025

Point72 Asset Management, L.P.

3.83M

2.61%

+3.42M

+840.86%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

3.00M

2.05%

-10.62K

-0.35%

Aug 31, 2025

Norges Bank Investment Management (NBIM)

2.26M

1.54%

-61.02K

-2.62%

Jun 30, 2025

Invesco Capital Management LLC

2.04M

1.39%

+32.06K

+1.59%

Jun 30, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Invesco Biotechnology & Genome ETF

Proporción5.49%

First Trust NASDAQ Pharmaceuticals ETF

Proporción4.45%

iShares Neuroscience and Healthcare ETF

Proporción4.25%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.53%

VanEck Biotech ETF

Proporción3.46%

Invesco Pharmaceuticals ETF

Proporción3.01%

iShares Health Innovation Active ETF

Proporción2.81%

First Trust Health Care Alphadex Fund

Proporción2.4%

ProShares Ultra Nasdaq Biotechnology

Proporción2.22%

Alger Russell Innovation ETF

Proporción2.21%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Biogen Inc?



Los cinco principales accionistas de Biogen Inc son:
The Vanguard Group, Inc. posee 17.21M acciones, lo que representa el 11.74% del total de acciones.
PRIMECAP Management Company posee 15.80M acciones, lo que representa el 10.78% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.19M acciones, lo que representa el 5.59% del total de acciones.
State Street Investment Management (US) posee 7.47M acciones, lo que representa el 5.09% del total de acciones.
Wellington Management Company, LLP posee 4.80M acciones, lo que representa el 3.27% del total de acciones.

¿Cuáles son los tres principales tipos de accionista de Biogen Inc?



Los tres principales tipos de accionista de Biogen Inc son:
The Vanguard Group, Inc.
PRIMECAP Management Company
BlackRock Institutional Trust Company, N.A.

¿Cuántas instituciones poseen acciones de Biogen Inc (BIIB)?



A fecha de 2025Q4, 1994 instituciones poseen acciones de Biogen Inc, con un valor de mercado combinado de aproximadamente 139.65M, lo que representa el 97.81% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -0.74%.

¿Cuál es la mayor fuente de ganancias de Biogen Inc?



El FY2025Q2, el segmento empresarial MS product revenues-TYSABRI generó la ganancia más alta para Biogen Inc, ascendiendo a 839.80M y representando el 31.74% de la ganancia total.

KeyAI

